Keyphrases
Atrial Fibrillation
100%
Paroxysmal Atrial Fibrillation
100%
Circulating Biomarkers
100%
False Discovery Rate
33%
Sex Differences
33%
Biological Pathways
33%
Patients Included
33%
Matrix metalloproteinase-3 (MMP-3)
33%
Blood Biomarkers
33%
Myoglobin
33%
Fatty Acid Binding Protein 4 (FABP4)
33%
Activated Leukocyte Cell Adhesion Molecule
33%
Validation Cohort
33%
Pathophysiological Mechanisms
16%
Heart Failure
16%
Diabetes
16%
Chemokines
16%
Hypertension
16%
Inflammatory Biomarkers
16%
AIMS™
16%
Atrial Fibrillation Progression
16%
Multivariable Logistic Regression
16%
Vascular Remodeling
16%
Adhesion
16%
Electrical Remodeling
16%
Atrial Fibrillation Treatment
16%
Hypercoagulability
16%
Preserved Ejection Fraction
16%
Extracellular Matrix Degradation
16%
Risk Profile
16%
Clinical Risk Profile
16%
CHA2DS2-VASc Score
16%
Enrichment Pathway Analysis
16%
INIS
women
100%
risks
100%
biological markers
100%
men
100%
patients
57%
matrices
42%
adhesion
42%
levels
28%
validation
28%
blood
28%
sex
28%
fatty acids
28%
proteins
28%
molecules
28%
biological pathways
28%
myoglobin
28%
data
14%
therapy
14%
hypertension
14%
inflammation
14%
interactions
14%
heart failure
14%
enrichment
14%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Atrial Fibrillation
100%
Paroxysmal Atrial Fibrillation
100%
Stromelysin
25%
Myoglobin
25%
Fatty Acid Binding Protein 4
25%
Activated Leukocyte Cell Adhesion Molecule
25%
Chemokine
12%
Congestive Heart Failure
12%
Hypercoagulability
12%
Vascular Remodeling
12%
Biochemistry, Genetics and Molecular Biology
Rapid Amplification of cDNA Ends
100%
Atrial Fibrillation
100%
Matrix Metalloproteinase
16%
Fatty Acid-Binding Protein
16%
Sex Difference
16%
Activated Leukocyte Cell Adhesion Molecule
16%
Myoglobin
16%
Heart Ejection Fraction
8%
Chemokine
8%